|
US5952294A
(en)
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
|
DE10005302A1
(de)
*
|
2000-02-07 |
2002-01-17 |
Gruenenthal Gmbh |
Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
|
|
BR0210149A
(pt)
|
2001-05-09 |
2004-06-29 |
Newbiotics Inc |
Pródrogas ativadas por deformilase de peptìdeo
|
|
DE10137488A1
(de)
*
|
2001-08-03 |
2003-02-20 |
Gruenenthal Gmbh |
Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
|
|
DE10236910A1
(de)
*
|
2002-08-12 |
2004-03-11 |
Grünenthal GmbH |
Substituierte 1,2,3,4-Tetrahydrochinolinderivate
|
|
CN103145616B
(zh)
*
|
2003-06-06 |
2015-09-30 |
菲布罗根有限公司 |
含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
CA2589363A1
(en)
|
2004-12-13 |
2006-06-22 |
Eli Lilly And Company |
Spiro derivatives as lipoxygenase inhibitors
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール，インク． |
Ｇｉｔｒ結合分子およびその使用
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
US8314234B2
(en)
|
2006-09-25 |
2012-11-20 |
Janssen Pharmaceutica N.V. |
Bicyclic pyrimidine kinase inhibitors
|
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
US20110065633A1
(en)
|
2008-01-30 |
2011-03-17 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
IN2015DN02826A
(enExample)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
DK2510010T3
(en)
|
2009-12-10 |
2015-12-14 |
Hoffmann La Roche |
Antibodies that bind to human CSF1R extracellular domain 4 and their use
|
|
WO2011107494A1
(de)
*
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
IN2014CN04174A
(enExample)
*
|
2011-12-22 |
2015-09-04 |
Novartis Ag |
|
|
MX2014008961A
(es)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Composiciones y metodos para utilizar inhibidores de csf1r.
|
|
WO2013122897A1
(en)
*
|
2012-02-13 |
2013-08-22 |
Amgen Inc. |
Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
CN102786512A
(zh)
*
|
2012-05-31 |
2012-11-21 |
中国人民解放军军事医学科学院毒物药物研究所 |
N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9757379B2
(en)
|
2012-11-14 |
2017-09-12 |
The Board Of Regents Of The University Of Texas System |
Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
|
|
WO2015022317A1
(en)
|
2013-08-13 |
2015-02-19 |
Philip Morris Products S.A. |
Smoking article comprising a blind combustible heat source
|
|
EP3417851B1
(en)
*
|
2013-09-09 |
2020-07-22 |
Peloton Therapeutics, Inc. |
Aryl ethers and uses thereof
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
CA2931085C
(en)
|
2013-12-16 |
2021-10-19 |
Peloton Therapeutics, Inc. |
Cyclic sulfone and sulfoximine analogs and uses thereof
|
|
US10098878B2
(en)
|
2014-10-10 |
2018-10-16 |
The Board Of Regents Of The University Of Texas System |
HIF-2α inhibitors for treating iron overload disorders
|
|
WO2016145032A1
(en)
*
|
2015-03-11 |
2016-09-15 |
Peloton Therapeutics, Inc. |
Compositions for use in treating pulmonary arterial hypertension
|
|
US10512626B2
(en)
|
2015-03-11 |
2019-12-24 |
Peloton Therapeautics, Inc. |
Compositions for use in treating glioblastoma
|
|
US10807948B2
(en)
|
2015-03-11 |
2020-10-20 |
Peloton Therapeutics, Inc. |
Aromatic compounds and uses thereof
|
|
WO2016145236A1
(en)
|
2015-03-11 |
2016-09-15 |
Peloton Therapeutics, Inc. |
Hif-2-alpha inhibitor polymorphs
|
|
EP3268362B1
(en)
|
2015-03-11 |
2021-10-20 |
Peloton Therapeutics, Inc. |
Substituted pyridines and uses thereof
|
|
US10335388B2
(en)
|
2015-04-17 |
2019-07-02 |
Peloton Therapeutics, Inc. |
Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
|
|
US9796697B2
(en)
|
2015-06-12 |
2017-10-24 |
Peloton Therapeutics, Inc. |
Tricyclic inhibitors of HIF-2-alpha and uses thereof
|
|
US20190048421A1
(en)
|
2015-09-21 |
2019-02-14 |
The Board Of Regents Of The University Of Texas System |
Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof
|
|
LT3399984T
(lt)
|
2016-01-08 |
2023-11-10 |
Arcus Biosciences, Inc. |
5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
|
|
WO2018031680A1
(en)
|
2016-08-10 |
2018-02-15 |
Fronthera U.S. Pharmaceuticals Llc |
Novel compounds, uses and methods for their preparation
|
|
WO2018067424A1
(en)
|
2016-10-03 |
2018-04-12 |
Arcus Biosciences, Inc. |
Inhibitors of adenosine 5'-nucleotidase
|
|
CN110022881B
(zh)
|
2016-11-18 |
2023-05-02 |
艾库斯生物科学有限公司 |
Cd73介导的免疫抑制的抑制剂
|
|
MX389798B
(es)
|
2017-01-20 |
2025-03-20 |
Arcus Biosciences Inc |
Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
|
|
EP3618829B1
(en)
|
2017-05-05 |
2023-06-07 |
Arcus Biosciences, Inc. |
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
|
|
CN110636846B
(zh)
|
2017-05-17 |
2023-05-16 |
艾库斯生物科学有限公司 |
用于治疗癌症相关疾病的喹唑啉吡唑衍生物
|
|
FR3071726B1
(fr)
*
|
2017-09-29 |
2020-09-04 |
Univ Paris Sud |
Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
CN108191860B
(zh)
|
2018-02-12 |
2019-12-10 |
中国医科大学 |
一种HIF-2α小分子抑制剂及其用途
|
|
TW202003430A
(zh)
|
2018-03-28 |
2020-01-16 |
美商佩樂敦治療公司 |
以ＨＩＦ-２-α之抑制劑降低消化系統發炎之方法
|
|
AU2019312296B2
(en)
|
2018-07-27 |
2025-05-29 |
Arcus Biosciences, Inc. |
Pyridone A2R antagonists
|
|
ES3053198T3
(en)
|
2018-08-27 |
2026-01-20 |
Arcus Biosciences Inc |
Cd73 inhibitors
|
|
US12171741B2
(en)
|
2018-09-11 |
2024-12-24 |
Nikang Therapeutics, Inc. |
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
|
|
EP3866927A4
(en)
|
2018-10-17 |
2022-07-27 |
Nikang Therapeutics, Inc. |
Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
|
|
CN112955130A
(zh)
|
2018-10-30 |
2021-06-11 |
佩洛通治疗公司 |
包含取代茚满的固体分散体和药物组合物及其制备和使用方法
|
|
EP3880685B1
(en)
|
2018-11-16 |
2025-06-18 |
Arcus Biosciences, Inc. |
Inhibitors of arg1 and/or arg2
|
|
CN109776607B
(zh)
|
2019-02-21 |
2021-06-04 |
青岛海洋生物医药研究院 |
芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
|
|
IL287258B2
(en)
|
2019-04-18 |
2026-01-01 |
Nikang Therapeutics Inc |
Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha
|
|
US20220274914A1
(en)
|
2019-07-22 |
2022-09-01 |
Nikang Therapeutics, Inc. |
Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors
|
|
EP4065569A1
(en)
|
2019-11-26 |
2022-10-05 |
Merck Patent GmbH |
Condensed thiophene derivatives as hypoxia inducible factor (hif) inhibitors
|
|
EP4069212A4
(en)
|
2019-12-04 |
2024-03-06 |
Arcus Biosciences, Inc. |
INHIBITORS OF HIF-2ALPHA
|
|
CN111303053B
(zh)
|
2020-03-16 |
2023-01-17 |
中国海洋大学 |
环戊并[d]嘧啶类化合物及其药学上可接受的盐、溶剂合物或者前药以及应用
|
|
CA3173831A1
(en)
|
2020-03-19 |
2021-09-23 |
Arcus Biosciences, Inc. |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|